胃癌依然是一个重大的公共卫生挑战,其特征为高发病率和高死亡率。肝脏是胃癌转移的主要靶器官,而腹膜、肺部和骨骼也是常见的转移部位。随着生物疗法的引入以及免疫治疗在转移性胃癌治疗中的应用,针对该病的治疗选择已显著增加。这些多样化的治疗方法均旨在改善患者的生活质量并延长生存期,体现了胃癌及其肝转移治疗领域的进展。这篇论文的意义在于关注了肝转移对胃癌免疫治疗效果的影响,这是一个临床上重要且亟待解决的问题。目前关于免疫疗法在胃癌中的研究较多,但专门针对肝转移患者的研究相对较少。该研究试图填补这一空白,并为临床决策提供参考。Gastric cancer continues to pose a significant public health challenge, marked by high incidence and mortality rates. The liver is the predominant organ for gastric cancer metastasis, while the peritoneum, lung, and bone are also frequent sites of metastatic spread. The advent of biotherapy and the incorporation of immunotherapy in treating metastatic gastric cancer have substantially expanded therapeutic options. These treatments aim to enhance patient quality of life and extend survival, reflecting advancements in the management of gastric cancer and its hepatic metastases. This paper’s significance lies in its focus on how liver metastasis influences the efficacy of immunotherapy in gastric cancer, an issue that is both clinically important and urgent. Although numerous studies have explored immunotherapy in gastric cancer, relatively few have specifically addressed patients with liver metastasis. This study seeks to address this gap and inform clinical decision-making.
